Currently, two non-selective HGFR TKIs have been approved: crizotinib (first approved in 2011) for ALK- and ROS1-positive NSCLC and cabozantinib (First approved in 2016) for thyroid cancer and kidney cancer [54]. This evidence concerns the gene ALK and thyroid cancer.